Breast cancer is the most commonly diagnosed cancer (estimated 2.3 million new cases in
2020) and the leading cause of cancer death (estimated 685,000 deaths in 2020) in women …

Gliomas, a prevalent category of primary malignant brain tumors, pose formidable clinical
challenges due to their invasive nature and limited treatment options. The current …

Introduction Most breast cancer-related deaths arise from triple-negative breast cancer
(TNBC). Molecular heterogeneity, aggressiveness and the lack of effective therapies are …

Triple-negative breast cancer (TNBC), a highly aggressive breast cancer subtype that lacks
estrogen receptor, progesterone receptor, and HER2 expression, does not respond to …

Cetuximab has an established role in the treatment of patients with recurrent/metastatic
colorectal cancer and head and neck squamous cell cancer (HNSCC). However, the long …

Immunoadoptive therapy with genetically modified T lymphocytes expressing chimeric
antigen receptors (CARs) has revolutionized the treatment of patients with hematologic …

Breast cancer (BC) emerged as one of the life-threatening diseases among females. Despite
notable improvements made in cancer detection and treatment worldwide, according to …

Bone morphogenetic proteins (BMPs) are potent signaling molecules initially described as
osteopromoting proteins. BMPs represent one of the members of the larger TGFβ family and …

Triple-negative breast cancer (TNBC) is a subset of breast cancer with aggressive
characteristics and few therapeutic options. The lack of an appropriate therapeutic target is a …

The success of conventional chimeric antigen receptor (CAR) therapy in the treatment of
refractory hematologic malignancies has triggered the development of novel exciting …